Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mast Cell Treatment in Post-tick Bite Illness
NCT07526558Phase 2Not yet recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketotifen, sodium cromoglycate in tick-borne disease, sponsored by University of North Carolina at Chapel Hill. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ketotifensodium cromoglycate
03
Conditions
tick-borne disease
Beyond the preview
Go deeper on NCT07526558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526558.